Technical Analysis for TARS - Tarsus Pharmaceuticals, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Slingshot Bearish | Bearish Swing Setup | 3.90% | |
| Crossed Above 200 DMA | Bullish | 3.90% | |
| Pocket Pivot | Bullish Swing Setup | 3.90% | |
| Volume Surge | Other | 3.90% | |
| Wide Bands | Range Expansion | 3.90% | |
| Oversold Stochastic | Weakness | 3.90% | |
| Doji - Bullish? | Reversal | 12.20% | |
| Wide Bands | Range Expansion | 12.20% |
| Alert | Time |
|---|---|
| Up 3% | about 8 hours ago |
| 60 Minute Opening Range Breakout | about 9 hours ago |
| Up 2% | about 9 hours ago |
| Up 1% | about 10 hours ago |
| Rose Above Previous Day's High | about 10 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 08/08/2024
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase IIb/III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. Tarsus Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Irvine, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Organ Systems Ophthalmic Malaria Rosacea Blepharitis Meibomian Gland
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Organ Systems Ophthalmic Malaria Rosacea Blepharitis Meibomian Gland
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 42.5 |
| 52 Week Low | 12.66 |
| Average Volume | 646,631 |
| 200-Day Moving Average | 25.95 |
| 50-Day Moving Average | 33.01 |
| 20-Day Moving Average | 29.62 |
| 10-Day Moving Average | 26.67 |
| Average True Range | 1.89 |
| RSI (14) | 41.52 |
| ADX | 26.19 |
| +DI | 20.98 |
| -DI | 27.43 |
| Chandelier Exit (Long, 3 ATRs) | 31.05 |
| Chandelier Exit (Short, 3 ATRs) | 30.10 |
| Upper Bollinger Bands | 35.80 |
| Lower Bollinger Band | 23.43 |
| Percent B (%b) | 0.39 |
| BandWidth | 41.77 |
| MACD Line | -2.17 |
| MACD Signal Line | -2.06 |
| MACD Histogram | -0.1093 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 31.17 | ||||
| Resistance 3 (R3) | 30.99 | 29.85 | 30.68 | ||
| Resistance 2 (R2) | 29.85 | 29.10 | 29.93 | 30.51 | |
| Resistance 1 (R1) | 29.04 | 28.64 | 29.45 | 29.22 | 30.35 |
| Pivot Point | 27.90 | 27.90 | 28.10 | 27.98 | 27.90 |
| Support 1 (S1) | 27.09 | 27.15 | 27.50 | 27.27 | 26.13 |
| Support 2 (S2) | 25.95 | 26.69 | 26.03 | 25.97 | |
| Support 3 (S3) | 25.14 | 25.95 | 25.80 | ||
| Support 4 (S4) | 25.32 |
